Table 2 Lifetime results of base-case analysis
Outcome | Current passive screening | Universal cholesterol screening | Universal genetic screening | Difference between universal cholesterol screening and current passive screening | Difference between universal genetic screening and current passive screening |
|---|---|---|---|---|---|
Not-fatal CHD | 692,586 | 662,541 | 603,821 | − 30,046 | − 88,766 |
Fatal CHD | 423,415 | 393,122 | 339,224 | − 30,293 | − 84,191 |
Total CHD events | 1,116,001 | 1,055,663 | 943,045 | − 60,339 | − 172,956 |
Number needed to screen | 4,359,000 | 435,899,980 | 435,899,980 | 431,540,980 | 431,540,980 |
Number needed to screen to prevent one CHD event | – | – | – | 7152 | 2495 |
Total LYs | 8,193,640 | 8,741,433 | 9,461,368 | 547,793 | 1,267,728 |
Total QALYs | 7,719,658 | 8,249,570 | 8,946,949 | 529,912 | 1,227,292 |
Screening costs (US$) | 444,707,418 | 22,597,552,805 | 42,063,824,990 | 22,152,845,387 | 41,619,117,572 |
Acute event costs (US$) | 2,984,385,478 | 2,531,027,048 | 1,905,310,714 | − 453,358,430 | − 1,079,074,764 |
Chronic management costs (US$) | 6,245,480,021 | 5,524,675,673 | 4,371,956,478 | − 720,804,348 | − 1,873,523,543 |
Treatment costs (US$) | 823,802,224 | 1,782,461,717 | 2,608,322,896 | 958,659,492 | 1,784,520,671 |
Total costs (US$) | 10,498,375,141 | 32,435,717,242 | 50,949,415,077 | 21,937,342,101 | 40,451,039,936 |
ICER (US$/LY) | – | – | – | 40,047 (25,790–65,777)a | 31,908 (18,196–54,812)a |
ICER (US$/QALY) | – | – | – | 41,398 (26,387–66,916)a | 32,960 (18,612–57,037)a |